A recent testing system by Robert Bosch GmbH became the latest company to roll out a Covid-19 test, it can gives result in just 2.5 hours instead of 2 days. The Less testing time, the more tests can be performs and that will help the total fatalities and treatment.
The test uses the Vivalytic molecular diagnostics platform, which made by Bosch’s health-care division. The device have been already in use hospitals, laboratories and medical practices to identify a range of bacterial and viral diseases including influenza and pneumonia.As the company stated,it will be available in Germany in April and sold in international markets.
“Infected patients can be identified and isolated faster,” Bosch Chief Executive Officer Volkmar Denner said Thursday in a statement. To develop the test, Bosch teamed up with Northern Irish medical equipment maker Randox Laboratories Ltd., its partner on Vivalytic.
- Russian President Vladimir Putin Nominated For Nobel Peace Prize, after Donald Trump
- 9-Year-Old Boy Kills Aunt In Pakistan In Suspected Dishonor
- All Flights From India and To India Banned by Saudi Arabia Due To Surge In Coronavirus Cases
- Facebook Spying on Instagram Users Through Cameras, Lawsuit Alleges
All of these offerings are so-called molecular diagnostic tests, which have confirmed the more than 500,000 cases known globally. They are the gold standard for diagnosing infections by looking for nucleic acids of the virus in people’s samples.
While highly accurate, they also require time, experienced technicians and materials ,including swabs, that are in short supply. Governments have been trying to limit the people who get tested to those deemed most at risk for complications.
Bosch said its rapid test can be performed entirely at the point of care. It was developed in six weeks and can diagnose 10 respiratory pathogens simultaneously, with an accuracy rate of more than 95%, according to the manufacturer.
As scientists are simultaneously assessing the reliability of blood-based tests that could turbocharge countries’ ability to diagnose people. These kits, which look for antibodies against the virus behind the pandemic, are less reliable than the molecular tests but cheaper and easier to make and distribute. Hoping it will be next steps for stop coronavirus.